Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Wilms tumor 1 antisense RNA (WT1-AS), also known as WT1-AS1, is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the Wilms tumor 1 (WT1) gene locus (Source: NCBI Gene ID 51352). It serves as a critical regulator of the WT1 gene, which encodes a transcription factor essential for urogenital development and frequently implicated in oncogenesis (Source: PubMed 26153814). WT1-AS modulates WT1 expression through several mechanisms, including the formation of RNA-DNA triplexes or the recruitment of epigenetic modifiers like EZH2 to the WT1 promoter, thereby influencing transcriptional activity (Source: PubMed 31114145). In clinical settings, dysregulation of WT1-AS is observed in various malignancies; for example, its overexpression in acute myeloid leukemia (AML) is linked to poor prognosis and chemoresistance (Source: PubMed 26153814). Conversely, in some contexts such as gastric cancer, WT1-AS has been shown to act as a tumor suppressor by inhibiting cell migration and invasion (Source: PubMed 30106434). As a therapeutic target, WT1-AS is being explored using RNA-targeting technologies like antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to modulate its levels and downstream oncogenic signaling (Source: PubMed 32454927). Its expression levels also hold potential as prognostic biomarkers for patient stratification and monitoring treatment response in both hematological and solid tumors.
Antisense-mediated degradation or functional inhibition of the long non-coding RNA transcript
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wilms tumor 1 antisense RNA (WT1-AS) (WT1-AS).